1 / 11

Aarkstore - Metastatic Renal Cell Carcinoma

The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Metastatic Renal Cell Carcinoma Browse full report @ http://bit.ly/1CZ3W8C

JustinSterling
Télécharger la présentation

Aarkstore - Metastatic Renal Cell Carcinoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category : Pharmaceuticals and Healthcare Aarkstore - Metastatic Renal Cell Carcinoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  2. Metastatic Renal Cell Carcinoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Renal Cell Carcinoma. A key objective of DelveInsights report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Metastatic Renal Cell Carcinoma. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Metastatic Renal Cell Carcinoma. While the leading brands, companies and chemicals are considered thoroughly, DelveInsights report also provides details on the Global API Manufacturers across the globe covering Drug Master FilingsofUS, Europe and API Manufacturers in Asia specifically China and India. The research analysis also presents the global sales forecasts data till 2016. Browse Complete Report – http://www.aarkstore.com/pharmaceuticals-healthcare/98056/metastatic-renal-cell-carcinoma-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2015

  3. Data Sources • The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts. • Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases. • Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. .

  4. Scope • A snapshot of the global Market therapeutics scenario for Metastatic Renal Cell Carcinoma. • A review of the marketed products under prescription for Metastatic Renal Cell Carcinoma, regulatory information and marketing status. • Coverage of global patent coverage and detailed commentaries on the US patent challenges. • Graphical representation of investigational products for patent expiry and market exclusivities across the globe. • Product profiles for marketed products for Metastatic Renal Cell Carcinoma with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details. • Coverage of API Manufacturers for Metastatic Renal Cell Carcinoma drugs in the United States, Europe and Asian Regions with location details. • Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Metastatic Renal Cell Carcinoma drugs.

  5. Reasons to buy • Evaluate the marketing status and exclusivity details of Metastatic Renal Cell Carcinoma key products to exploit opportunities for generic drug development opportunities. • Identify and understand important and diverse types of therapeutics under Phase III development for Metastatic Renal Cell Carcinoma. • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Metastatic Renal Cell Carcinoma. • API intelligence over marketed drugs for Metastatic Renal Cell Carcinoma and gaining primary intelligence over active ingredients manufacturers across the globe. • API intelligence over leading Phase III Pipeline drugs. • Develop and design strategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.

  6. Table of Content • Indication Overview • Marketed Drugs • Marketed Details of Drugs by Application Type • Marketed Details of Drugs (NDA) by Marketing Status • Marketed Details of Drugs by Patent Expiration Timeline • Active Pharmaceutical Ingredient (API) Manufacturers Assessment • API Manufacturers by United States Drug Master File (US DMF) Status • API Manufacturers by US DMF Status (Drug Specific) • API Manufacturers in Europe by Country • API Manufacturers in India by State • API Manufacturers in China by Province • Marketed Details of Approved Drugs by Geography • Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs

  7. List of Tables • Metastatic Renal Cell Carcinoma Therapeutic Market, US, Marketed Drugs by Application Type, 2015 • Metastatic Renal Cell Carcinoma Therapeutic Market, US, Marketed Drugs by Marketing Status, 2015 • Metastatic Renal Cell Carcinoma Therapeutic Market, US, (Year), 2015 • Metastatic Renal Cell Carcinoma Marketed Drugs, API Manufacturers by US DMF Status, 2015 • Metastatic Renal Cell Carcinoma Marketed Drugs, US DMF Status Drug Specific (Number), 2015 • Metastatic Renal Cell Carcinoma Drugs, API Manufacturers, Europe by Country, 2015 • Metastatic Renal Cell Carcinoma Drugs, API Manufacturers, India by State, 2015 • Metastatic Renal Cell Carcinoma Drugs, API Manufacturers, China by Province, 2015 • Metastatic Renal Cell Carcinoma Drugs, API Manufacturers by Geography 2015

  8. List of Figures • Metastatic Renal Cell Carcinoma Therapeutic Market, US, Marketed Drugs by Application Type (%), 2015 • Metastatic Renal Cell Carcinoma Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2015 • Metastatic Renal Cell Carcinoma Therapeutic Market, US, (Year), 2015 • Metastatic Renal Cell Carcinoma Marketed Drugs, API Manufacturers by US DMF Status (%), 2015 • Metastatic Renal Cell Carcinoma Marketed Drugs, US DMF Status Drug Specific (Number), 2015 • Metastatic Renal Cell Carcinoma Drugs, API Manufacturers, Europe by Country, 2015 • Metastatic Renal Cell Carcinoma Drugs, API Manufacturers, India by State, 2015 • Metastatic Renal Cell Carcinoma Drugs, API Manufacturers, China by Province, 2015

  9. Related reports: • Partnerships, Licensing, Investments and M&A Deals and Trends for January 2015 in Pharmaceuticals • EpiCast Report: Sepsis - Epidemiology Forecast to 2023 • Myasthenia Gravis Global Clinical Trials Review, H1, 2015 • Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2015 • OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020 - Event-Driven Update • Global Epinephrine Autoinjector Market 2015-2019 • Human Growth Hormone Market in the US 2015-2019 • Global Acute Coronary Syndrome (ACS) Market 2015-2019 • Global Automated External Defibrillator Market 2015-2019 • Global Gaucher Disease Market 2015-2019

  10. Metastatic Renal Cell Carcinoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Published: Feb 2015 | 100 Pages Metastatic Renal Cell Carcinoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Renal Cell Carcinoma. Price

  11. Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news

More Related